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The importance of gene expression profiling for the development of personalized medical 
approach for diagnosis and treatment of Cutaneous T-Cell Lymphoma (CTCL)
I Litvinov,1 Y Zhou,3 TS Kupper2 and D Sasseville1 1 Dermatology, McGill University, 
Montreal, QC, Canada, 2 Dermatology, Brigham and Women’s Hospital, Boston, MA and 3 
Dermatology, University of British Columbia, Vancouver, BC, Canada
Cutaneous T-Cell Lymphoma (CTCL) is a rare, but potentially devastating malignancy. The patho-
genesis for this cancer remains poorly elucidated. While most patients present with stage I disease, 
only 15-20% of these patients will progress to higher stages, whereas the rest will enjoy near normal 
life expectancy and an indolent disease course. Currently it is not possible to predict which patients 
will progress and which patients will have stable disease. Also, it is often difficult to diagnose early 
and/or erythrodermic CTCL and distinguish this cancer from benign inflammatory dermatoses that 
can mimic CTCL clinically. In the past we conducted microarray and RT-PCR analyses of gene 
expression in biopsy specimens from 60 stage I-IV CTCL patients. These patients were prospectively 
followed for 6 years. The initial RT-PCR analysis revealed three distinct transcription profile clusters 
that were associated with different clinical outcomes. In the current work we test the expression 
of ~240 genes that were previously reported to play an important role in CTCL carcinogenesis 
within the above-described three cluster/signature model of gene expression and also compare the 
expression of 27 selected genes between CTCL and benign dermatoses. Our findings demonstrate 
that 52 of these genes can be classified into cluster 1-3 expression patterns and such expression is 
congruent with their suggested biological role in CTCL pathogenesis. Moreover, 17 genes CCL18, 
CCL26, FYB, T3JAM, MMP12, LEF1, LCK, ITK, GNLY, IL2RA, IL-26, IL-22, CCR4, SYCP1, GTSF1, 
STAT5A and TOX are able to molecularly distinguish CTCL from benign dermatoses and identify 
patients, who are at risk of progression. In conclusion, this study combined with other gene expres-
sion analyses prepares the foundation for the development of personalized molecular approach for 
diagnosis and treatment of CTCL.    
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Genome-wide analysis of DNA methylation in Sézary syndrome
MH Vermeer,1 W Zoutman,1 S Boonk,1 K Tensen,1 M Bagot,2 L van der Fits,1 J Goeman,3 
B Heijmans4 and R van Doorn1 1 Dermatology, LUMC, Leiden, Netherlands, 2 Dermatology, 
Hopital Saint-Louis, Paris, France, 3 Medical statistics, LUMC, Leiden, Netherlands and 4 
Molecular Epidemiology, LUMC, Leiden, Netherlands
Sézary syndrome (SS) is an aggressive type of CTCL characterized by erythroderma, generalized 
lymphadenopathy, and the neoplastic T cells (Sézary cells) in the skin, lymph nodes and peripheral 
blood. The prognosis of patients with SS is poor with a disease-specific 5-year survival around 20%. 
The implication of epigenetic alterations such as aberrant DNA methylation in the pathogenesis 
of haematopoietic malignancies is increasingly recognized. Aberrant methylation of CpG islands 
located in gene promoters is associated with transcriptional downregulation affecting a multi-
tude of genes in cancer cells. We characterized the DNA methylomes of malignant T cells from 
peripheral blood of 15 SS patients and benign T cells from 4 healthy individuals and 3 patients 
with benign erythroderma (BE) using beadchip technology interrogating the methylation status of 
485,000 methylation sites at single-nucleotide resolution. The epigenomic landscapes revealed 
a multitude of differentially methylated sites in SS versus benign T cells. Comparative statistical 
analysis identified 126 gene promoters that were significantly and frequently hypermethylated in 
SS including established tumor suppressor genes. These results were confirmed by bisulfite PCR 
for 12 genes in the original group of 15 SS patients. In an independent group of 20 SS patients and 
controls including 10 BE patients specificity of these epigenetic alterations for SS was confirmed. 
Using demethylating agents we found that promoter methylation was associated with gene silencing. 
Clinically, the differentially methylated sites in SS could be applied as epigenetic biomarkers in 
the early diagnosis of this disease. The epigenetic instability of SS cells provides a rationale for its 
sensitivity to epigenetic drugs. Our study demonstrates an array of highly recurrent DNA methylation 
alterations in SS with potential diagnostic applications and suggests that aberrant DNA methylation 
contributes to the pathogenesis of this CTCL.    
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Th1 cytokine-mediated cancer prevention stabilizes the genome 
E Brenner,1 D Gransheier,1 F Essmann,2 H Braumüller,1 T Wieder,1 J Bauer,1 M Röcken1 and 
K Schulze-Osthoff2 1 Dermatology, Eberhard Karls University, Tuebingen, Germany and 2 
Biochemistry, Eberhard Karls University, Tuebingen, Germany
Immunotherapy with tumor-associated antigen (TAA) specific T-helper-1 (Th1) cells can reduce the 
tumor burden in melanoma patients. Previous data by us show that the cancer control induced by 
Th1 cytokines results from the super-induction of the tumor suppressor p16INK4a. To determine the 
mechanisms underlying the interferon-γ (IFN-γ)- and tumor necrosis factor (TNF)-mediated growth 
arrest in cancers, we studied carcinomas in mice, in which the expression of SV40 large T antigen 
2 (Tag2) under the rat insulin promoter 1 (RIP) disturbs the cell cycle control through complete 
inhibition of the tumor suppressors p53 and Rb. In vitro treatment of isolated β-cancer cells with 
IFN-γ and TNF stabilized the hypophosphorylated state of Rb and suppressed the transcription factor 
E2F2. As Rb hypophosphorylation should block cell cycle progression, we asked whether immuno-
therapy with TAA-specific Th1 cells can prevent the accumulation of genomic alterations in β-cancer 
isolates. To analyze this question, we performed array comparative genomic hybridization (CGH) 
of tumors. As expected, we detected multiple quantitative chromosomal aberrations in cancers 
of sham-treated RIP-Tag2 mice. In clear contrast, β-cancers from mice treated with TAA-specific 
Th1 cells remained genetically stable without developing chromosomal aberrations. Cancers from 
knock-out mice showed that this stabilization was strictly dependent on IFN-γ and TNF. Moreover, 
β-cancers isolated from Th1-treated mice remained growth arrested in vitro, whereas β-cancer cells 
from sham-treated mice grew exponentially. Here, the abnormal DNA content was confirmed by 
flow cytometry. Thus, Th1 immunity can protect from cancer progression by stabilizing the chro-
mosome, probably through restoration of the Rb pathway.    
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ABCB5 inhibition sensitizes Merkel cell carcinoma cells to chemotherapy-induced apoptosis 
S Kleffel,1 N Lee,1 C Lezcano,3 K Sobolewski,1 H Mueller,1 A DoRosario,2 L Wang,2 
MH Frank,1 GF Murphy3 and T Schatton1 1 Department of Dermatology, Brigham and 
Women’s Hospital, Boston, MA, 2 Dana-Farber/Brigham and Women’s Cancer Center, 
Harvard Medical School, Boston, MA and 3 Department of Pathology, Brigham and Women’s 
Hospital, Boston, MA
The development of chemotherapy resistance poses a major barrier to improving patient outcomes 
in the systemic treatment of Merkel cell carcinoma (MCC). Here, we demonstrate that ATP–bind-
ing cassette member B5 (ABCB5) identifies chemoresistant MCC subpopulations and show that 
ABCB5 inhibition sensitizes MCC cells to carboplatin- and etoposide-induced killing. ABCB5 mRNA 
and protein expression were detected in established MCC lines and clinical MCC specimens. In 
vitro, ABCB5+ MCC cells exhibited preferential survival after treatment with the standard-of-care 
agents, carboplatin and etoposide. Monotherapy of MCC-bearing mice with carboplatin or etopo-
side resulted in markedly increased ABCB5 levels compared to controls when residual disease 
was detected. Consistent with these findings, analysis of patient-matched MCC biopsy specimens 
obtained pre- and post-chemotherapy revealed enhanced frequencies of ABCB5+ MCC cells in 
post-chemotherapy biopsies. Mechanistically, antibody-mediated ABCB5 blockade reversed resis-
tance of MCC cells to carboplatin and etoposide in vitro. In MCC xenograft-bearing mice, ABCB5 
inhibition sensitized tumor cells to carboplatin and etoposide-induced apoptosis and inhibited 
tumor growth compared to either chemotherapy alone. Our results establish ABCB5 as a novel 
chemoresistance mechanism in MCC and identify ABCB5 inhibition as a promising therapeutic 
approach for improving treatment response in this malignancy.    
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Dissecting the role of iASPP, a novel regulator of epidermal homeostasis, in keratinocyte 
skin carcinogenesis 
D Robinson, CA Harwood and D Bergamaschi Cutaneous Research, Blizard Institute, 
London, United Kingdom
Keratinocyte skin cancer (KSC), comprising cutaneous squamous (cSCC) and basal cell (BCC) car-
cinoma is currently the most common malignancy in the UK. P53 is frequently mutated in cSCC. 
The iASPP oncoprotein, an inhibitory member of the ASPP (apoptosis stimulating protein of p53) 
family, is a key inhibitor of p53 and NF-kB and elevated expression has been documented in many 
cancers. Recently, our group unveiled a novel autoregulatory feedback loop between iASPP and p63 
in the stratified epithelia; this involves two microRNAs, miR-574-3p and miR-720, and is critical for 
epidermal homeostasis. In view of this newly-identified iASPP-p63 axis, we hypothesised a potential 
role for dysregulation of this feedback loop in the pathogenesis of keratinocyte malignancies. We 
also aimed to assess the role of iASPP in human cSCC. Protein and mRNA expression patterns were 
assessed in a panel of 10 cSCC cell lines generated by our group. In addition, immunostaining of 
iASPP and p63 was performed in 73 cSCC clinical samples of variable differentiation status. Our 
data reveal an overall increase in expression of iASPP and ΔNp63 in cSCC but also suggest a sig-
nificant alteration of the cellular localisation of iASPP with consequent alterations of its function. 
To further assess the effects mediated by the iASPP/p63 axis, iASPP and p63 have been silenced 
by RNAi technology in a subset of cSCC cell lines. Expression patterns, functionality (apoptosis, 
cell motility and invasiveness), gene and microRNA expression analysis were investigated in these 
cellular models. Our data suggest that while direct effects of iASPP and p63 upon each others 
expression are maintained in cSCC, epigenetic dysregulation of the feedback loop at the microRNA 
level may be occurring. These findings provide potential future directions for development of clinical 
biomarkers and novel therapeutic targets for cSCC and may ultimately provide the tools for tackling 
the increasing morbidity and mortality associated with this malignancy.    
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Complement Factor I promotes progression of cutaneous squamous cell carcinoma 
P Riihilä,1 L Nissinen,1 M Farshchian,1 A Kivisaari,1 M Kallajoki,2 R Grénman,3 S Meri,4 
S Peltonen,1 J Peltonen5 and V Kähäri1 1 Department of Dermatology, University of Turku 
and Turku University Hospital, Turku, Finland, 2 Department of Pathology, Turku University 
Hospital, Turku, Finland, 3 Department of Otorhinolaryngology - Head and Neck Surgery, 
Turku University Hospital, Turku, Finland, 4 Haartman Institute, University of Helsinki, 
Helsinki, Finland and 5 Department of Anatomy and Cell Biology, University of Turku, 
Turku, Finland
The incidence of cutaneous squamous cell carcinoma (cSCC) and its precancerous forms is rising 
worldwide. Here, we have investigated the role of complement components in the progression 
of cSCC. Analysis of cSCC cell lines (n=8) and normal human epidermal keratinocytes (n=11) 
with whole transcriptome profiling (SOLiD), quantitative RT-PCR, and western blotting showed 
marked overexpression of complement factor I (CFI) in cSCC cells. Immunohistochemical analysis 
for CFI showed stronger tumor cell specific staining intensity in invasive sporadic cSCCs (n=83) 
and recessive dystrophic epidermolysis bullosa-associated cSCCs (RDEBSCC, n=7) than in prema-
lignant epidermal lesions (actinic keratoses, n=64), in cSCC in situ (n=65), normal skin (n=9) and 
benign epidermal papillomas (seborrheic keratoses, n=39) in vivo. The expression level of CFI was 
higher in aggressive Ha-ras-transformed cell line (RT-3) than in less tumorigenic HaCaT cell lines 
(HaCaT, A5, II-4) at mRNA and protein level. The expression of CFI was upregulated by IFN-γ and 
IL-1β in cSCC and Ha-ras-transformed cells. Knockdown of CFI expression inhibited migration and 
proliferation of cSCC cells and was associated with the inhibition of basal ERK1/2 activation. The 
growth of human cSCC xenograft tumors was potently inhibited by knockdown of CFI expression 
in vivo. These results show evidence for the role of CFI in the progression of cSCC and suggest it as 
a potential therapeutic target in cSCC.    
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Diverse roles for laminin 332 subunits in squamous cell carcinoma 
M Caley,1 V Martins,1 K Moore,2 J Marshall2 and E O’toole1 1 Centre for Cutaneous Research, 
Barts and the London SMD, Queen Mary University of London, london, United Kingdom 
and 2 Barts Cancer Institute, Barts and the London SMD, Queen Mary University of London, 
London, United Kingdom
The role of Laminin 332 in tumour development is poorly understood. It has been identified as both 
vital for tumour progression and to act as a tumour suppressor. Patients with Junctional epidermolysis 
bullosa caused by mutations in laminin 332 have a high incidence of squamous cell carcinoma 
(SCC). To investigate the role of laminin 332 in SCC we generated stable knockdowns (KD) of each 
Laminin 332 chain (LamA3, LamB3 & LamC2) in cutaneous SCC cell lines. Using these cells we 
studied their role in cell attachment, motility, in vitro and in vivo invasion, integrin expression, cel-
lular signalling and global gene expression using RNA-seq. The loss of any Lam332 chain reduced 
cell attachment with the greatest reduction seen with LamA3 and LamC2. The loss of LamA3 and 
LamC2 increased cell motility whereas loss of LamB3 had no effect on motility. Loss of LamA3 and 
LamC2 increased invasion both in vitro (collagen gels) and in vivo (murine xenografts) with distinct 
patterns of invasion in each cell line. LamA3 and LamC2 KD increased EMT in vivo with increased 
Vimentin and loss of E-Cadherin. LamB3 KD was characterised by increased differentiation in vivo 
with increased Keratin 10 and involucrin. Each cell line demonstrated a unique pattern of integrin 
expression with increased b1 integrin in LamA3 and LamC2 KD and increased a6 in LamA3 and 
LamB3 KD. Activated pFAK was increased in LamA3 and LamC2 KD with a matched increase in 
Src. Downstream from FAK changes were seen in Rac, Akt and Wnt pathways. RNA-seq analysis 
allowed us to identify genes involved in cancer progression differentially regulated due to the 
loss of each chain of laminin 332. Of particular interest was the increased expression of MMPs 
and pro-inflammatory cytokines in the invasive LamA3 and LamC2 KD. Our data provides strong 
evidence that loss of each chain of laminin 332 leads to distinct phenotypic and genotypic changes 
highlighting the importance of studying each laminin 332 chain in future studies.    
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A case of primary cutaneous large B-cell lymphoma presenting as leg cellulitis and non-heal-
ing ulcers
Q Chen,1 P Sng2 and S Pang3 1 National Skin Centre, Singapore, Singapore, 2 Pathology, 
Singapore General Hospital, Singapore, Singapore and 3 Dermatology, Singapore General 
Hospital, Singapore, Singapore
Primary cutaneous large B-cell lymphoma (PCLBCL) is a rare and aggressive neoplasm. We report 
a case of a 67-year-old Indian male who presented with one month history of leg cellulitis and 
non-healing ulcers on the background of multiple rapid progressing nodules on his left leg for 
3-4 months. Histology from skin biopsy showed diffuse infiltrate in the dermis and subcutis with 
malignant B lymphocytes that were CD20 positive, MUM-1 positive and FOX-P1 positive. Those 
features were consistent with PCLBCL. In view of the location on leg, PCLBCL-leg type was the most 
likely diagnosis. However the malignant cells were largely negatively stained for BCL-2. Therefore 
there was debate whether it should be categorized under either PCLBCL-leg type or PCLBCL-others, 
with former usually stained positively for BCL-2. The staging showed infiltration of the ipsilateral 
draining inguinal and external iliac lymph nodes in PET-CT scan. PCLBCL is a rare and aggressive 
neoplasm. The location on the leg, the round-cell morphology defined as the predominance of 
centroblasts and immunoblasts over large centrocytes, and multiple skin lesions were identified 
as adverse prognostic factors in PCLBCL. In addition, some study proposed that BCl-2 expression 
was the strongest independent prognostic factor of survival in PCBCL. However the absence of 
positive BCL-2 staining did not guarantee a favourable prognosis. Our patient was likely to have 
poor prognosis in view of his multiple cutaneous tumours, location on the leg, rapid progression 
and metastasis to regional lymph nodes. PCLBCL is a rare and aggressive B-cell lymphoma. We 
report here a case of rapid progressing PCLBCL in an Indian male patient, who presented as leg 
cellulitis and non-healing ulcers. This case report emphasises the important of differential diagnosis 
of PCLBCL in non-healing ulcers and atypical cellulitis.    
110
A surprising pro-tumorigenic function of activated Nrf2 in keratinocytes 
F Rolfs,1 M Huber,2 A Kühne,3 E Haertel,1 U Sauer,3 R Dummer,4 H Beer,4 D Hohl,2 
S Werner1 and M Schäfer1 1 Institute of Molecular Health Sciences, Department of Biology, 
ETH Zurich, Zurich, Switzerland, 2 Service de Dermatologie et Vénéréologie, Hôpital de 
Beaumont, Université de Lausanne, Lausanne, Switzerland, 3 Institute for Systems Biology, 
Department of Biology, ETH Zurich, Zurich, Switzerland and 4 Department of Dermatology, 
University Hospital Zurich, Zurich, Switzerland
Nrf2 is a central regulator of the cellular antioxidant defense system through the regulation of 
antioxidant enzymes, cytoprotective proteins and transporters. Compounds that activate Nrf2 are 
therefore in clinical trials as anti-cancer drugs. We tested the consequences of Nrf2 activation on 
DMBA/TPA-induced skin tumorigenesis using transgenic mice expressing a constitutively active (ca) 
Nrf2 mutant in keratinocytes. Expression of genes involved in detoxification of DMBA and of reactive 
oxygen species (ROS) was increased in these mice, resulting in a reduction of DMBA-induced DNA 
mutations and ROS damage. However, despite these anti-tumorigenic activities, Nrf2 activation only 
slightly reduced tumor incidence and multiplicity. To avoid the influence of Nrf2 on detoxification 
of the mutagen, we next crossed caNrf2 transgenic mice with mice expressing the oncogenes of 
the human papilloma virus (HPV) 8 in keratinocytes. Surprisingly, these mice showed enhanced 
tumorigenesis, most likely due to the increased levels of glutathione, of several amino acids and 
of metabolites of the pentose phosphate pathway that we identified by mass spectrometry. These 
metabolic changes had no influence on proliferation and differentiation of keratinocytes, but they 
promoted survival of pre-malignant keratinocytes. Taken together, our data reveal an unexpected 
pro-tumorigenic function of activated Nrf2 during early skin tumorigenesis. Therefore, the use of 
Nrf2 activating substances for the prevention of skin cancer should be re-evaluated.    
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Ago2 in cytokine-induced senescence in human cancers
J Pahl, H Braumüller, E Brenner, S Weidemann, T Wieder and M Röcken Dermatology, 
University Medical Center, Tübingen, Germany
Senescence is an essentially irreversible cell cycle arrest that protects against malignant transfor-
mation. Several cancer types inhibit senescence by repressing silencing genes important for cell 
proliferation, particularly by repressing the E2F/Rb1 complex. Recent studies have provided a link 
between argonaute protein 2 (Ago2), a principal component of the RNA-induced silencing com-
plex, and gene silencing in human cancer cells. Our previous studies revealed that the T-helper-1 
cytokines IFN-γ and TNF can induce senescence by upregulating the CDK inhibitor p16INK4a and 
consecutive inactivation of the E2F family of transcription factors. As very little is known about 
possible endogenous signals and senescence induction by exogenous stimuli we analyzed the 
involvement of Ago2 in this process. First we investigated the effect of IFN-γ and TNF on the human 
rhabdomyosarcoma cell line A204 and the human breast cancer line MCF-7. In a BrdU uptake assay, 
both cell lines showed significantly reduced proliferation rates when treated with both cytokines 
compared with untreated carcinoma cells. To verify that the cell cycle arrest is permanent we 
performed growth arrest assays. After withdrawal of both cytokines A204 and MCF-7 cancer cells 
did not start to proliferate again even after 3 passages without IFN-γ and TNF. Trypanblue exclusion 
showed that the cells did not die but staid growth arrested. To demonstrate that Ago2 is involved 
in senescence we stained Ago2 at several points after cytokine treatment and followed the translo-
cation from the cytoplasm into the nucleus. As the Ago2 protein was described as being constantly 
expressed we performed double-stainings with the proliferation marker Ki67. In non-proliferating 
senescent cells we could observe a prominent translocation from the cytoplasm into the nucleus. 
This translocation started at 24h and prolonged up to 72h. Our results show that the argonaute 
protein Ago2 is involved in cytokine-induced senescence and may work as a co-repressor of the 
E2F/Rb repressor complex in human cancer cells.    
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Analysis of STAT4 expression in cutaneous T-cell lymphoma (CTCL) patients and patient-de-
rived cell lines
I Litvinov,1 B Cordeiro,1 H Zargham,1 K Pehr,1 Y Huang,4 Y Zhou,4 N Ødum,3 TS Kupper,2 
A Woetmann3 and D Sasseville1 1 Division of Dermatology, McGill University, Montreal, QC, 
Canada, 2 Harvard Skin Disease Research Center, Brigham and Women’s Hospital, Boston, 
MA, 3 Department of International Health, Immunology, and Microbiology, University of 
Copenhagen, Copenhagen, Denmark and 4 Department of Dermatology and Skin Science, 
University of British Columbia, Vancouver, BC, Canada
Deregulation of STAT signaling has been implicated in the pathogenesis for a variety of cancers, 
including CTCL. Recent reports indicate that loss of STAT4 expression is an important prognostic 
marker for CTCL progression and is associated with the acquisition of T helper 2 cell phenotype 
by malignant cells. However, little is known about the molecular mechanism behind the down-
regulation of STAT4 in this cancer. In the current work we test the expression of STAT4 and STAT6 
via RT-PCR in CTCL lesional skin samples and in immortalized patient-derived cell lines. In these 
malignant cell lines we correlate the expression of STAT4 and STAT6 with the T helper (Th) phe-
notype markers and test the effect of Histone Deacetylase (HDAC) inhibitors and siRNA-mediated 
knock down of miR-155 on STAT4 expression. Our findings demonstrate that STAT4 expression 
correlates with Th1 phenotype, while STAT6 is associated with the Th2 phenotype. Our results 
further document that STAT4 and STAT6 genes are inversely regulated in CTCL. Treatment with 
HDAC inhibitors upregulates STAT4 expression, while at the same time decreases STAT6 expression 
in MyLa cells. Also, siRNA-mediated knock down of miR-155 leads to upregulation in STAT4 expres-
sion in MyLa cells. In summary, our results suggest that loss of STAT4 expression and associated 
switch to Th2 phenotype during CTCL progression may be driven via aberrant histone acetylation 
and/or upregulation of oncogenic miR-155 microRNA.    
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CD147 depletion induces the phosphorylation of EGFR by down regulating cdc25c
M Hatanaka,1 Y Higashi,1 K Kawai,1 J Su,2 W Zeng,2 X Chen2 and T Kanekura1 1 Dermatology, 
Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan 
and 2 Dermatology, Xiangya Hospital, Central South University, Changsha, China
The RAF-MEK-ERK pathway plays an important role in oncogenesis. The activating mutation of 
BRAF, which constitutively activates the RAF-MEK-ERK cascade, is identified in 70% of malignant 
melanomas (MMs). CD147/basigin, an integral plasma membrane protein belonging to the immuno-
globulin superfamily, is highly expressed on MM cells. It promotes cellular proliferation and tumor 
growth. We investigated the correlation between CD147 and the RAF-MEK-ERK pathway by using 
the A375 MM cell line which harbors the activating mutation of BRAF. Phosphorylation of EGFR 
was up-regulated and MEK and cdc25C were down-regulated by CD147 silencing in A375 cells. 
While cell growth was inhibited by both the EGFR inhibitor erlotinib and by CD147 silencing, we 
demonstrate synergistic growth inhibition in CD147 knock-down cells. Our findings suggest that 
the combination of EGFR and CD147 inhibition might be useful in BRAF-mutant MM.    
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Claudin-11 regulates invasion of cutaneous squamous carcinoma cells
L Nissinen,1 E Siljamäki,1 L Raiko,1 R Ala-aho,1 R Grénman,2 J Peltonen,3 S Peltonen1 
and V Kähäri1 1 Department of Dermatology, University of Turku and Turku University 
Hospital, Turku, Finland, 2 Department of Otorhinolaryngology - Head and Neck Surgery, 
Turku University Hospital, Turku, Finland and 3 Department of Anatomy and Cell Biology, 
University of Turku, Turku, Finland
The incidence of keratinocyte derived skin cancer, cutaneous squamous cell carcinoma (cSCC), 
is increasing globally. Epidermal keratinocytes are connected by tight junctions (TJ), consisting of 
transmembrane proteins, such as claudins (CL) and occludin, and of zona occludens (ZO) which 
connect TJs to actin cytoskeleton. Expression of TJ proteins in normal human epidermal keratino-
cytes (NHEK, n=4) and cSCC cell lines (n=8) was determined with SOLiD whole transcriptome 
sequencing and Affymetrix analysis. ZO-1 was expressed both in NHEKs and in cSCC cell lines. 
Claudin-11 (CL-11) was expressed in NHEKs and primary cSCC cells (n=5) but not in metastatic 
cSCC cells (n=3). Furthermore CL-11 mRNA expression was significantly downregulated in cSCC 
tumors (n=6) compared to normal skin (n=7; p=0.004). Knock-down of CL-11 in cSCC cells revealed 
increased cancer cell invasion (p=0.009). Expression of CL-11 was also detected in immortalized 
non-tumorigenic keratinocyte-derived cell line (HaCaT) and the expression was lower in tumorigenic 
Ha-ras-transformed HaCaT cells (A5, II4, and RT3) with high basal ERK1/2 activation. Inhibition 
of ERK1/2 pathway with MEK1 inhibitor PD98059 resulted in restoration of CL-11 expression in 
Ha-ras-transformed HaCaT cells. The expression of ZO-1 was downregulated in metastatic RT3 
cells. These results provide evidence, that the loss of CL-11 expression in cSCC cells might serve 
as a biomarker for an advanced invasive stage of cSCC.    
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Common genetic variations of multiple basal cell carcinomas
J Verkouteren,1 L Pardo,1 A Uitterlinden,2 B Hofman3 and T Nijsten1 1 Dermatology, Erasmus 
MC University Medical Center, Rotterdam, Netherlands, 2 Internal Medicine, Erasmus 
MC University Medical Center, Rotterdam, Netherlands and 3 Epidemiology, Erasmus MC 
University Medical Center, Rotterdam, Netherlands
Recent genome-wide association studies (GWAS) have identified several loci involved in suscep-
tibility to basal cell carcinoma (BCC). Whether these or other loci confer susceptibility to multiple 
BCC (mBCC, > 1 BCC) is unknown. We aimed to identify genes that contribute to an increased risk 
of mBCC. We included 9,810 participants from the Rotterdam Study. Of these, 747 had one BCC 
and 472 had mBCC. All cases were histopathologically confirmed. First, we used a candidate gene 
approach (CGA) in cases with mBCC versus one BCC and in cases with at least one BCC (n=1,219) 
versus no BCC (n=8,591). We selected 19 genes (8,302 markers) that were previously associated 
with BCC in well-powered GWAS. We used a gene-based logistic regression adjusting for age, 
gender and principal components. Next, to identify new loci for mBCC, we conducted a GWAS on 
mBCC versus one BCC. The markers consisted of over 30M genotyped/imputed single nucleotide 
polymorphisms (SNP). We used SNP-based logistic regression and adjusted for the same covariates 
as in the CGA. Of the 19 genes previously associated with BCC, six genes (TERT-CLPTM1L, KRT5, 
PADI6, TGM3 and TP53) were significantly associated with BCC compared to no BCC in our CGA. 
In sharp contrast, only one gene (UBAC2) was significantly associated with mBCC. Through our 
GWAS on mBCC we identified two top signals (P≤3.89x10-7) located on chromosomes 2 and 3. The 
most significant SNP was rs78857623, which is an intronic variant in the FHIT gene (P=1.19x10-7). 
The CGAs point out that the genetic composition differs between people who develop only one BCC 
compared to people who develop mBCC. In addition, the GWAS performed on mBCC identified 
a novel susceptibility gene (FHIT), which is a tumor suppressor gene associated to other cancers. 
This is the first GWAS conducted on histopathologically confirmed cases with mBCC. Our results 
provide a promising candidate region for follow-up studies to confirm our findings.    
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Dasatinib promotes apoptosis of cutaneous squamous carcinoma cells 
M Farshchian,1 L Nissinen,1 R Grénman2 and V Kähäri1 1 Dermatology and MediCity 
Research Laboratory, University of Turku and Turku University Hospital, Turku, Finland and 
2 Otorhinolaryngology, Head and Neck Surgery, University of Turku and Turku University 
Hospital, Turku, Finland
Receptor tyrosine kinases are desirable targets for treatment of cancer. Imatinib mesylate is an 
inhibitor of multiple tyrosine kinases including ABL, KIT, and platelet-derived growth factor recep-
tors indicated for treatment of chronic myeloid leukemia (CML) and gastrointestinal stromal tumors 
(GIST). Nilotinib and dasatinib are second-generation BCR-ABL inhibitors with higher potency 
regarding BCR-ABL kinase inhibition used in the treatment of imatinib-resistant CML. Recent studies 
have shown the antineoplastic effect of dasatinib alone or in combination with other antineoplastic 
drugs in the treatment of solid tumors such as breast, prostate cancer and melanoma. We have 
studied the effect of dasatinib, nilotinib and imatinib on viability and signaling pathways of cell 
lines (n=7) established from cutaneous SCC (cSCC). Cell viability assay showed that dasatinib 
significantly reduced the number of viable cells of all cSCC cell lines in a time-dependent (24h, 
48h, and 72h) and dose-dependent (0.1μm, 1μM, 10μM) manner. Nilotinib reduced the viability 
of cSCC cells only with the highest concentration (10μM), whereas imatinib had no effect. TUNEL 
assay showed that dasatinib (0.1μM) induced apoptosis in cSCC cells after 6 h treatment. Inhibition 
of Src activation was noted 10 min after treatment of cSCC cells with dasatinib. Moreover, dasatinib 
potently inhibited phosphorylation of ERK1/2 (60 min) and p38 MAPK (10 min). These findings 
provide evidence for the potent effect of dasatinib on viability of cSCC cells suggesting dasatinib 
as a therapeutic candidate for patients with cSCC.    
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DNA methylation and hydroxymethylation regulate E-cadherin/CDH1 expression in squa-
mous cell carcinoma of the skin
H Fujiwara and M Ito Dermatology, Niigata University, Niigata, Japan
DNA methylation down-regulates mRNA transcription by 5-methylcytosine, 5-mC, in promoter 
sequence, and takes significant roles in development, aging, and carcinogenesis. Recently the exis-
tence of 5-hydroxymethylcytosine, 5-hmC, in human genome was discovered; it is now considered 
that 5-hmC is an intermediate compound in demethylation cascade of 5-mC; Tet family proteins, Tet 
1, 2, or 3, oxidate 5-mC into 5-hmC, then it is turned into 5-cytosine. We established new method, 
non-isotopic cytosine extension assay for 5-hmC, previously, and reported that 5mC/hmC ratio in 
skin is firmly conserved in age; 5-mC/5-hmC ratio would be closely regulated to maintain homeo-
stasis in normal condition. Because of the methodological difficulty in analyzing 5-hmC, the 5-hmC 
data in skin tumor is sparse, and the in situ analysis has not been conducted. With the extracted 
genomic DNA from squamous cell carcinoma of the skin, we disclosed that 5-mC and 5-hmC do 
exist in E–cadherin/CDH1 promoter with methylation-specific and hydroxymethylation-specific 
PCR. Next, we established an in situ detection method of 5-mC, methylation detection-in situ 
hybridization, MDISH, with combining in situ hybridization and 5-mC sensitive restriction enzyme 
digestion in situ. For in situ detection of 5-hmC, hydroxymethylation detection-in situ hybridiza-
tion, hMDISH was established combining MDISH and in situ glucosylation of 5-hmC. We could 
demonstrate that E-cadherin/CDH1 promoter was specifically methylated in SCC tumor cell in 
situ, and E-cadherin/CDH1 mRNA and protein expression were reduced in these cells. E-cadherin/
CDH1 promoter hydroxymethylation was also observed in the tumor cells albeit in small number. 
In conclusion E-cadherin/CDH1 expression was suppressed in SCC through the deregulation of 
promoter methylation, 5-C/5-mC/5-hmC imbalance.    
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DNA repair specifies regional mutation frequencies in human cancer
Z Christina,1 E Purdom2 and RJ Cho3 1 Knight Cancer Center, Portland, OR, 2 Statistics, 
University of California, Berkeley, Berkeley, CA and 3 Dermatology, University of California, 
San Francisco, San Francisco, CA
Somatic mutations in cancer are more frequent in heterochromatic and late-replicating portions 
of the genome, possibly because these areas are insulated from repair machinery, suffer from 
replication deficiencies or are mutagenized at higher rates. We find these regional disparities in 
mutation density are virtually abolished within transcriptionally silent DNA of cutaneous squamous 
cell carcinomas (cSCCs) arising in an XPC-\- background, which lack global genome nucleotide 
excision repair (GG-NER). In transcribed regions of XPC-\- genomes, where transcription-coupled 
nucleotide excision repair (TC-NER) remains active, regional mutational disparities contain a 30-fold 
greater contribution from differences in TC-NER than in wild-type tumors, revealing DNA repair as 
the primary cause. Strikingly, increasing levels of transcription reduce mutation density of genes 
embedded within heterochromatin domains to those levels observed in euchromatin. Therefore, 
we establish that transcription exerts dominance over chromatin state in enhancing DNA repair of 
specific proto-oncogenes, modulating cancer risk in an assessable manner.    
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Expression of langerhans cells, dermal  dendritic   cells and plasmacytoid  dendritic  cells in 
early stage mycosis fungoides : A case – control study 
M Fawzy,1 MI Attia,1 RA Hegazy,1 A El Tawdy1 and I Katayama2 1 Dermatology, Cairo 
University, Cairo, Egypt and 2 Dermatology, Osaka University, Osaka, Egypt
One possible mechanism explaining the prolonged disease development in early stage mycosis fun-
goides (MF) could be that the patient’s immune system controls tumour progression by an antitumour 
immune response, in which dendritic cells are thought to actively participate. To focus on studying 
the 3 lineages of dendritic cells (DCs); Langerhans cells (LCs), dermal dendritic cells (DDCs), and 
plasmacytoid dendritic cells (pDCs), through determining the expression of their markers CD1a, 
factor XIIIa and CD123 respectively in the early stage MF. 16 patients with early stage MF and 6 
controls were included. Skin biopsies underwent immunohistochemical staining for CD1a, Factor 
XIIIa and CD123. The mean number of positive cells of both CD1a+ve LCs and factor XIIIa DDcs 
were significantly higher in the MF patients in comparison to the controls (P=0.001, P=0.013) 
respectively. However, no significant difference was documented regarding the mean number 
of CD123+ve pDCs between MF patients (0.77± 0.95) and controls (0.22±0.47) (P=0.13). ROC 
analysis revealed that the area under the curve of CD1a+ve LCs and factor XIIIa DDcs was 0.948 
and 0.0.844, with the best cutoff values 3.167 and 5.83, that achieved sensitivity 100%, specificity 
67%, and sensitivity 100%, specificity 67% respectively. A possible role is played by LCs, DDCs 
and pDCs in the pathogenesis of MF. However, whether the DCs appeared in reaction to tumor 
cells to antagonize their progression or to be a source for chronic antigenic stimulation resulting 
in the immune escape of tumor cells and perpetuation of the disease needs more clarification.   
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HSP72 is a possible target for combination therapy with HDAC inhibitor
K Fujii,1 N Suzuki,2 M Idogawa,3 T Kondo,4 K Iwatsuki2 and T Kanekura1 1 Department 
of Dermatology, Kagoshima University Graduate School of Medical and Dental Sciences, 
Kagoshima, Japan, 2 Department of Dermatology, Okayama University Graduate School 
of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, 3 Department of 
Medical Genome Sciences, Research Institute for Frontier Medicine, Sapporo Medical 
University, Sapporo, Japan and 4 Division of Pharmacoproteomics, National Cancer Center 
Research Institute, Tokyo, Japan
Histone deacetylase inhibitors (HDACi) are emerging anticancer agents for cutaneous T cell lym-
phoma (CTCL), while those effects are variable among the patients. Therefore identification of a 
target for combination therapy with HDACi is needed. We identified that the expression of heat 
shock 70 kDa protein 1A (HSPA1A, HSP72) was increased in valproic acid (VPA)-resistant cell 
lines by the two-dimensional differential in gel electrophoresis analysis of 33 lymphoid cell lines. 
KNK437, an inhibitor of HSP70, synergistically enhanced the apoptosis induced by not only VPA 
but vorinostat in a CTCL cell line, Hut78. HDACi-induced growth inhibition was significantly 
enhanced in HSP72 stably knockdown Hut78 cells compared to MOCK cells. HDACi-induced apop-
tosis, caspase-3 cleavage, histone H3 and H4 acetylation, reduction of mitochondrial membrane 
potential were enhanced in HSP72 knockdown cells. Baseline expression level of bcl-2 was lower 
in knockdown cells. That of bcl-xl and XIAP was not changed, while HDACi-induced attenuations 
of these proteins were more evident in knockdown cells. In conclusion, HSP72 is a possible target 
for combination therapy with HDACi.    
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Increased frequency of regulatory T cells with impaired suppressive capacity after PUVA in 
cutaneous T-cell lymphoma
PA Vieyra-Garcia, G Mayer, H Pressl, E Reginato, NA Schweintzger, I Bambach, A Hofer, 
A Gruber-Wackernagel, L Cerroni and P Wolf Dermatology, Medical University of Graz, 
Graz, Austria
Cutaneous T cell lymphoma (CTCL) is a disease of proliferative CD4 T cells homing in the skin 
that slowly invade lymphoid tissue, peripheral blood and other organs. Psoralen plus UVA (PUVA) 
photochemotherapy induces apoptosis of malignant cells and is highly effective in the initial stages 
of the most common CTCL malignancy mycosis fungoides (MF). However, PUVA is also known 
to induce transient immunosuppression with the up-regulation of CTLA-4, nevertheless, its exact 
underlying therapeutic mechanism in MF is not yet well understood. We addressed this issue by 
examining skin biopsies and blood of MF patients before and during PUVA treatment. At baseline 
we found a low number of Foxp3+ cells in the lymphoid infiltrate in the skin, however, the relative 
frequency of these cells increased in the remaining infiltrate after several weeks of treatment. The 
frequency of Treg cells ascended after treatment also in the blood, conversely, their suppressive 
capacity decayed. Moreover, we saw a decrease of TH17 (RORγT+) cell frequency and the moni-
toring of the frequency of malignant cells (measured by expression of CD7 and CD26) in blood did 
not show a significant difference comparing before and after treatment values, although the patients 
exhibited remission of lesions. In a mouse lymphoma model we have been able to replicate tumour 
formation and after PUVA we have observed higher frequencies of Treg cells and lower frequencies 
of activated CD8 T cells in spleen and lymph nodes. These findings suggest an involvement of Treg 
cells in the therapeutic mechanisms of PUVA. Whereas PUVA can increase the levels of Treg cells 
in the blood and skin, the treatment seems to impair Treg function. Taken together, PUVA may 
normalize the compromised immune surveillance of MF patients.    
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Infrared Radiation Confers Resistance to UVB-induced Apoptosis in Normal Human 
Melanocyte 
S Kimeswenger,1 D Födinger,1 A Schwarz,2 H Pehamberger1 and C Jantschitsch1 1 
Divistion of Dermatology, Medical University Vienna, Vienna, Austria and 2 Department of 
Dermatology, Kiel University, Kiel, Austria
It is generally accepted that ultraviolet radiation (UVR) damages DNA and thus is a contributor to 
the development of non-melanoma skin cancer. In contrast, the correlation between melanoma and 
UVR is not fully understood. In addition to UVR, which makes up for about 7 % of the solar energy 
reaching the earth’s surface, the sun emits infrared radiation (IR) which accounts for approximately 
55 %. From previous studies there is evidence that IR might enhance the development of non-epi-
thelial skin cancer and possibly also of melanoma. The aim of the present study was to investigate 
the impact of IR on UVR-induced apoptosis and DNA repair in normal human melanocytes since 
malignant transformation depends on the balance between these two effects. Melanocytes of dif-
ferent donors were exposed to 250 J cm-2 of IR-A (780–1,400 nm), 0.4 J cm-2 of UVB (290–320 
nm) or both simultaneously. Apoptotic effects were determined using cell death ELISA and FACS 
analysis 24 hours after exposure. UVR-induced DNA damage was detected applying South-Western 
dot blot analysis using antibodies against cyclobutane pyrimidine dimers 6 hours after exposure. 
In contrast to treatment with UVB alone, melanocytes exposed to IR-A and UVB simultaneously 
exhibited a significantly reduced apoptotic rate. IR-A did not influence UVR-induced DNA damage. 
The observed effects might enhance the survival of severely UVR-damaged melanocytes which in 
turn might eventually contribute to melanomagenesis.    
123
Inhibition of Aurora Kinase-A in skin carcinogenesis
D Sheneman,1 J Fernandez,1 B Podell,2 DR Roop1 and E Torchia1 1 Dermatology, University 
of Colorado Anschutz Medical Campus, Aurora, CO and 2 Microbiology, Immunology and 
Pathology, Colorado State Univeristy, Fort Collins, CO
Currently, there are few effective therapeutic options for recurrent or metastatic Squamous Cell 
Carcinomas (SCCs). We have previously modeled the formation of high-risk SCCs in mice by the 
overexpression of the mitotic regulator Aurora Kinase A (Aurora-A) or by the induction of mutant 
p53 alleles in skin. Analysis of tumors in these mouse models indicated that the inhibition of 
mitotic regulators such as Aurora-A might be effective against the formation high-risk carcinomas. 
To test this possibility, we characterized the premalignant skin in mutant p53 mice after a short 
period of tumor promotion. Following daily application of Tetradecanoylphorbol acetate (TPA), 
increased levels of proliferation and marked hyperplasia of the epidermis was evident relative to 
wild type controls, indicating enhanced proliferative capacity of keratinocytes with altered p53 
function. We then determined the contribution of Aurora-A to the proliferation of premalignant 
epidermis using cre-recombinase/lox technology in mice carrying mutant p53 and floxed Aurora-A 
alleles. Concomitant treatment of TPA with the ablation of Aurora-A resulted in marked epidermal 
thickening, increased mitotic index and accumulation of phosho-histone H3 (marker for M-phase 
cells) without a subsequent increase in the cell number per surface area of the epidermis. Deletion 
of Aurora-A did not reduce BromodeoxyUridine incorporation indicating that entry into the cell 
cycle remained unaffected. Lastly, cellular pleomorphism with frequent large epithelial cells and 
multinucleation, nuclear pleomorphism with prominent nucleoli, and disorganization of the epi-
dermal layers including abnormal differentiation and dyskeratosis were also evident. In summary, 
we have characterized the initial proliferative changes associated with premalignant skin harboring 
mutant p53 and deleted for Aurora-A. These studies may serve as a platform to test the efficacy of 
small molecule inhibitors of mitotic regulators against the development of aggressive skin cancers.   
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Interaction of CD100 and its receptor Plexin-B1/2 in the pathogenesis of Cutaneous Squa-
mous Cell Carcinoma 
C Zhang and W Li Xijing Hospital, Fourth Military Medical University, Xi’an, China
Cutaneous squamous cell carcinoma (CSCC) accounts for 60% of total skin malignant tumors, and 
the prevention and treatment of CSCC is still very difficult. CD100 (Semaphorin 4D), one member of 
the Semaphorin family, is expressed on the surface of many cell types. In the microenvironment that 
is deficient in CD100, the growth and migration capability of tumor cells were severely disturbed. 
Plexin-B1 and Plexin-B2, the receptors of CD100, have been found to be expressed on many cell 
types including many tumors. Previous studies suggested that the interaction between CD100 and 
Plexin-B2 promoted the proliferation and differentiation of keratinocytes (KCs). And the interaction of 
CD100 and its receptors Plexin-B1/B2 had been shown to participate in the pathogenesis of various 
tumors. Expression of CD100 on T cells and regulatory T cells (Treg) in PBMC and tumor tissue 
of CSCC patients were analyzed by FACS. For in vitro function studies, Plexin-B1 and Plexin-B2 
siRNA interference fragment were constructed and CSCC cell lines were transfected subsequently. 
The proliferation of treated cells was detected by CCK-8 analysis, and migration and invasion were 
analyzed by transwell experiment. The expression of signaling molecules downstream CD100 or 
Plexin-B1/B2 were analyzed by Western blot and Real-time PCR. CD100 on cultured cells were 
analyzed by adding soluble CD100 into the culture of CSCC cell lines. CSCC cell lines showed 
significantly reduced proliferation and migration after transfection with Pleixn-B1 or Plexin-B2 
siRNA. While soluble CD100 promoted the proliferation and migration of CSCC cell lines greatly. 
Levels of signaling molecules of ERK and Akt pathways were increased in soluble CD100 treated 
CSCC cells,and the FACS data showed that the number of Tregs in CSCC tissue was increased, and 
the expression level of CD100 on Tregs in CSCC tissue were lower than other T cells. Interaction 
of CD100 and Plexin-B1/B2 participate in the pathogenesis of CSCC by both promoting the prolif-
eration and migration of malignant KCs and by regulating the function of Tregs.    
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Investigating the Mechanism of Action of Ingenol Mebutate in cutaneous SCC
SN Freiberger,1 G Iotzova-Weis,1 P Cheng,1 Q Liu,1 R Dummer,1 M Levesque,1 K Skak2 and 
G Hofbauer1 1 Department of Dermatology, University Hospital Zurich, Zurich, Switzerland 
and 2 Biological Research, LEO Pharma A/S, Ballerup, Denmark
Squamous cell carcinoma (SCC) is the second most common human cancer and second leading 
cause of skin cancer death in the US. Recently a new drug for topical treatment of AK, Picato® 
with the active compound ingenol mebutate (IM), was approved which has the advantage of being 
applied for only 2-3 days and causes a short period of local skin reactions. The mechanism of action 
has been shown to be inducing cell death and eliciting a specific PKC-dependent immune reaction. 
However, the direct effects of IM on keratinocytes and AK/SCC cells have not been elucidated. 
Here we are investigating pathways that we found to be involved in the mechanism of action of 
IM. We address direct treatment effects on cell functionality by analyzing viability. Interestingly, 
growth curves show a drop of viability at a concentration of 100nM while cells appear healthier 
at lower and higher concentrations. To investigate the mechanism of action we performed a gene 
expression array to determine differential expression patterns upon treatment. From this profile we 
chose several genes that were upregulated in keratinocytes and SCC cells upon treatment to inves-
tigate the molecular mechanism of action. To delineate participating pathways we ran a pathway 
analysis on the gene expression profile and found PKC and MAPK to be involved. According to 
this we found PKCd and ERK phosphorylated in keratinocytes and SCC cells due to treatment and 
phosphorylation of ERK could be prevented by a PKC inhibitor. We used inhibitors to block these 
pathways and analyzed cell viability and expression of the chosen genes. Inhibition of PKC/MEK/
ERK partially rescued the viability of treated cells and prevented the drug-dependent upregulation 
of the chosen genes. We conclude that IM causes different effects on the cells depending on the 
concentration used, being rather direct cell death at high concentrations while lowering viability 
at intermediate concentrations by activating PKC/MAPK signaling in keratinocytes and SCC cells.   
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Investigation of a possible role for human papillomavirus as a repressor of notch signalling 
in skin carcinogenesis
K Purdie,1 AP South,2 AT McHugh,2 D Xue,2 JH Dayal,2 I Leigh,2 C Proby2 and CA Harwood1 
1 Centre for Cutaneous Research, Blizard Institute, Queen Mary University of London, 
London, United Kingdom and 2 Division of Cancer Research, Ninewells Hospital and Medical 
School, Dundee, United Kingdom
A cofactor role for human papillomavirus (HPV) with ultraviolet radiation (UVR) in the aetiology 
of cutaneous SCC (cSCC) is supported by epidemiological data confirming a significant associa-
tion with beta genus HPVs. Possible pathogenetic mechanisms include interactions between host 
cellular proteins and HPV oncoproteins. For example, UV-induced pro-apoptotic activity of the 
mitochondrial effector BAK is abrogated by HPV E6–mediated degradation. Beta genus HPV E6 
oncoproteins have also been shown to repress NOTCH signalling in vitro through their interaction 
with the transcriptional co-activator Mastermind-like 1 (MAML1). NOTCH mutation has recently 
been identified as a common early event in cSCC development. We hypothesised that HPV E6-de-
pendent inhibition of MAML1 transactivation may represent an alternative mechanism for abrogating 
NOTCH signalling in the absence of NOTCH mutation. The mutational status of NOTCH1 and 
NOTCH2 and the presence of HPV DNA were investigated in a series of 79 cSCC. A majority 
(66%; 52/79) of the samples were positive for beta genus HPV while 86% (68/79) had NOTCH1 
and / or NOTCH2 mutations. HPV DNA was detected in a higher proportion of NOTCH wild-type 
(82%, 9/11) than NOTCH mutant (63%, 43/68) tumours, although the difference was not statisti-
cally significant (p=0.3), likely due to the small number of NOTCH wild-type samples. Our data 
suggest that NOTCH mutation is the major mechanism by which the NOTCH signalling pathway 
is repressed in cSCC. Further investigation of a larger sample series should determine whether beta 
HPV prevalence is indeed higher in NOTCH wild-type tumours, which may further support role for 
HPV in the abrogation of NOTCH signalling and the pathogenesis of cSCC.    
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MicroRNA-31 is overexpressed in cutaneous squamous cell carcinoma and regulates cell 
motility and colony formation ability of tumor cells 
A Wang, N Xu Landen, F Meisgen, W Lohcharoenkal, M Ståhle, E Sonkoly and A Pivarcsi 
Dept of Medicine, Dermatology Unit, Karolinska Institutet, Stockholm, Sweden
Cutaneous squamous cell carcinoma (cSCC) is a malignancy of epidermal keratinocytes that is 
responsible for approximately 20% of skin cancer-related death yearly. We have previously com-
pared the microRNA (miRNA) expression profile of cSCC to healthy skin and found the dysregulation 
of miRNAs in human cSCC. In this study we show that miR-31 is overexpressed in cSCC (n=66) 
compared to healthy skin (n=34) and precancerous skin lesions (actinic keratosis, n=12). LNA in 
situ hybridization revealed that miR-31 was specifically up-regulated in tumor cells. Mechanistic 
studies of with inhibition of endogenous miR-31 in human metastatic cSCC cells revealed suppressed 
migration, invasion and colony forming ability, whereas overexpression of miR-31 induced these 
phenotypes. These results indicate that miR-31 regulates cancer-associated phenotypes of cSCC 
and identify miR-31 as a potential target for cSCC treatment.    
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Phospholipase C beta4 regulates invasion and proliferation in cutaneous SCC in vivo
EL Ruban,1 MA Balogun,1 V Martins,1 M Caley,1 C Raimondi,2 E O’toole1 and M Falasca2 
1 Centre for Cutaneous Research, Barts and the London SMD, Queen Mary University of 
London, london, United Kingdom and 2 Barts and the London SMD, Queen Mary University 
of London, london, United Kingdom
Phospholipase C beta 4 (PLC-β4) belongs to the phospholipase C family of enzymes, regulating 
cell growth, differentiation and migration through activation of protein kinase C (PKC) and intra-
cellular calcium release. We found using gene expression arrays that PLCB4 is highly expressed 
in SCC cells with knockdown of type VII collagen, modelling recessive dystrophic epidermolysis 
bullosa (RDEB) known to be associated with aggressive SCC. Our hypothesis is that PLC-beta4 
may play a regulatory role in SCC tumourigenesis. Using RNAi technology, we achieved transient 
and lentiviral stable knock-down (KD) of PLC-β4 (siPLC-β4 and shPLC-β4) in cutaneous SCC cell 
lines. SCC cells with KD of PLC-β4 had decreased proliferation without altering differentiation or 
inducing apoptosis. Live-imaging confocal microscopy demonstrated that PLC-β4 KD cells had 
absent intracellular calcium-release following specific activation of the PLC-β4 pathway. Moreover, 
various functional assays, including monolayer scratch, Transwell® and organotypic 3D cultures, 
revealed significantly decreased cell migration and invasion in SCC cells with KD of PLC-β4 with 
reduced cell adhesion. Xenografts of stable knockdown cells demonstrated decreased invasion, 
proliferation and angiogenesis. These findings suggest that PLC-β4 regulates SCC proliferation, 
invasion and angiogenesis and is a therapeutic target in SCC    
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Possible association between actinic keratosis and polymorphism   rs7208422  ( c.917AÇT, 
p.N306l) of EVER2 gene in non - epidermodysplasia verruciformis patients. 
A Kalinska-Bienias,1 C Kowalewski,1 G Kostrzewa,2 M Malejczyk,3 R Ploski2 and S Majewski3 
1 Department of Dermatology and Immunodermatology, Medical University of Warsaw, 
Warsaw, Poland, 2 Department of Medical Genetics, Medical University of Warsaw, Warsaw, 
Poland and 3 Department of Dermatology and Venereology, Medical University of Warsaw, 
Warsaw, Poland
In recent years, two novel genes, EVER1 and EVER2, have been detected, mutations in which 
play a role in development of epidermodysplasia verruciformis (EV), a genodermatosis associated 
with precancerous lesions/skin cancers. Recently it has been found that, polymorphism rs7208422 
(c.917A→T, p.N306l) in EVER2 is related to an increased risk of squamous skin cancers (SCC) in 
non-EV patients. We hypothesized, that this polymorphism might be also associated with actinic 
keratosis (AK). The aim of the study was to determine whether polymorphism rs7208422 of the 
EVER2 gene is associated with AK in non-EV patients. We genotyped rs7208422 in 65 patients 
with AK and 280 control group using RT-PCR. We detected a possible association between AK and 
rs7208422 TT (frequency of the genotype TT in AK was 38.5% and 26.3% in the controls, OR=1.75, 
p=0.056 for recessive model of inheritance). We also found an association between rs7208422 
TT and the age in which AK appeared and the extent of AK. This variant was more frequent in AK 
which appeared in patients below 70 compared to those above 70 (OR=3.14, p=0.031 for recessive 
model; OR=2.05, p=0.04 for allelic comparison) and more frequent in AK comprising of more than 
3 areas (OR=3.14, p=0.031 for recessive model; OR=2.34, p=0,01 for allelic comparison). These 
associations remained significant in a multivariate regression analysis, which evaluated the com-
pound point of these parameters showing, that both of them were independently associated with 
genotype TT (p=0.031). Summarizing this study could point to the potential role of polymorphism 
rs7208422 (c.917A→T, p.N306l) of EVER2 gene in AK.    
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Premature aging features rescue by inhibition of NADPH oxidase activity in XPC deficient 
mice 
M Hosseini, W Mahfouf, M Serrano-Sanchez, H Raad, A Taieb and HR Rezvani Inserm 
U1035, Bordeaux, France
Progeroid syndromes are a group of diseases characterized by signs of premature aging. Most of 
these syndromes include defects in different DNA repair systems such as nucleotide excision repair 
(NER). Among NER diseases, xeroderma pigmentosum type C (XP-C) is a rare hereditary disease 
characterized mostly by a predisposition to skin cancers and accelerated photoaging, but little is 
known about premature aging in this disease. Comparing young and old mice, we found that the 
level of progerin and p16INK4a expression, b-galactosidase activity and reactive oxygen species (ROS), 
which are increased with age, are higher in young Xpc-/- than young Xpc+/+ mice. The expression 
level of mitochondrial complexes and mitochondrial functions in the skin of young Xpc-/- was low 
as in control aged Xpc+/+animals. Furthermore, metabolic profile in young Xpc-/- resembled to the 
profile found in the aged Xpc+/+ mice. Our study further reveals that premature aging features in 
young Xpc-/- mice were mostly rescued by inhibition of NADPH oxidase 1 (NOX1) activity using 
a novel NOX1 peptide inhibitor. Our results suggest that the continuous oxidative stress due to 
overactivation of NOX1 plays a causative role in the underlying pathophysiology and NADPH 
oxidase inhibitors, although not correcting the gene defect, may be of help in limiting accelerated 
aging in XP-C patients.    
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PTCH1 mutations impairs specifically base excision repair in Gorlin’s fibroblasts 
W Rachidi,1 T Douki2 and A Charazac2 1 Univ. Grenoble Alpes, Grenoble, France and 2 
CEA, Grenoble, France
Gorlin syndrome is an autosomal dominant disorder whose incidence is estimated at about 1 per 
60 000 individuals. It is characterized by radiosensitivity and an increased predisposition to basal 
cell carcinomas (BCCs). Mutations in the tumor suppressor gene PTCH1 are responsible for these 
clinical manifestations. As several genetic mutations in the DNA repair genes are responsible of 
photo or radiosensitivity and high predisposition to cancers, we hypothesized that these effects 
in Gorlin syndrome might be due to a defect in the DNA damage response (DDR). Therefore, the 
objective of this work is to study the effect of PTCH1 mutations on the DNA damage response in 
order to better understand the cellular and molecular mechanisms leading to hyper-radiosensitivity 
and high susceptibility to various cancers in Gorlin’s patients. To that aim, we used fibroblasts from 
Gorlin patients or healthy individuals and compared their radiosensitivity, their resistance to several 
stresses, the extent of DNA damage, the expression of base excision repair (BER) genes and the 
corresponding enzymatic activity. Gorlin’s fibroblasts showed high radiosensitivity upon exposure 
to ionizing radiation and also less resistance to oxidative stress agents when compared to controls. 
However, no difference in cell viability was shown after exposure to UVB or bleomycin. As BER is 
responsible for the repair of oxidative DNA damage, we decided to assess the BER mechanisms in 
Gorlin’s fibroblasts. Interestingly, the levels of both BER gene expression and BER protein activity 
were drastically decreased in Gorlin’s fibroblasts with respect to controls. Our results suggest that 
PTCH1 mutation in Gorlin’s fibroblasts does not only impairs the BER system under basal conditions 
but also prevents the cell from adapting to an oxidative environment. The synergistic effects of 
increased ROS, accumulated DNA damage and impaired DNA repair could participate and partly 
explain, the cancer-prone phenotype in Gorlin’s syndrome. To our knowledge, this is the first study 
showing the impact of PTCH1 mutations on the oxidative DNA repair capacities.    
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Quantification of CD8+ T cells and FOXP3+ regulatory T cells in actinic keratoses and cuta-
neous squamous cell carcinomas
C Lai,1 A Albibas,1 R Behar,1 S August,1 ME Polak,1 MR Ardern-Jones,1 J Theaker,2 
A Al-Shamkhani3 and E Healy1 1 Dermatopharmacology, University of Southampton, 
Southampton, United Kingdom, 2 Histopathology, University Hospital Southampton NHS 
Foundation Trust, Southampton, United Kingdom and 3 Cancer Sciences, University of 
Southampton, Southampton, United Kingdom
Non-melanoma skin cancer is the most common cancer worldwide. Cutaneous squamous cell 
carcinomas (SCC) are immunogenic tumours, and our previous work demonstrated the presence 
of immunosuppressive regulatory T cells (Tregs) in the peritumoral immune infiltrate of skin SCCs. 
Actinic keratoses (AKs) are highly prevalent in Caucasian populations, and have the potential to 
progress to SCCs. In this study, immunohistochemistry and ImageJ quantification of T cell subsets 
in AKs (n=44) and cutaneous SCCs (n=79) was undertaken. AKs were surrounded by perilesional 
lymphocytic infiltrates consisting of CD4+ T cells (57% of immune infiltrate), CD8+ T cells (37.6%) 
and FOXP3+ Tregs (24.1%). The degrees of dysplasia in these AKs were histologically graded as 
mild, moderate or severe, with no differences in the frequencies of CD4+ T cells, CD8+ T cells 
and FOXP3+ Tregs seen between the groups (p=0.25, p=0.08 and p=0.62 respectively). Skin SCCs 
contained fewer CD8+ T cells (31.8% of the peritumoral immune infiltrate) than AKs (p=0.046), but 
there were similar frequencies of FOXP3+ Tregs (29.2% of SCC immune infiltrate, p=0.13). Flow 
cytometry of immunocytes isolated from fresh skin SCCs (n=36) confirmed similar CD8+ T cell and 
FOXP3+ Treg proportions. Fewer CD8+ T cells were observed in poorly differentiated SCCs compared 
with moderately differentiated SCCs (26.4% versus 36.9% of immune infiltrate, p=0.019). In addi-
tion, increased FOXP3+ Treg frequencies were demonstrated in poorly differentiated tumours (well 
differentiated=19.0%, moderately differentiated=30.7%, poorly differentiated=37.4%, p=0.0097), 
and correlated with depth of tumour invasion (r=0.33, p=0.0041). These results demonstrate that 
Tregs and CD8+ T cells are present in AKs and cutaneous SCCs, and the frequencies of these cells 
in the perilesional infiltrate may play a role in skin cancer progression.    
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Rosuvastatin: is it a promising agent for melanoma chemoprevention?
M Uzarska,1 R Debski,2 T Drewa1 and R Czajkowski3 1 Department of Tissue Engineering, 
Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland, 2 Department of 
Pediatric Hematology and Oncology, Laboratory of Clinical and Experimental Oncology, 
Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland and 3 Department 
of Dermatology, Sexually Transmitted Diseases and Immunodermatology, Collegium 
Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland
Evidence from preclinical and clinical studies indicates that statin use may be associated with 
lower incidence of melanoma. Inhibition of HMG-CoA reductase decreases the synthesis not only 
of cholesterol but also other intermediates of mevalonate pathway that are involved in protein pre-
nylation. Considering the role of prenylated proteins in regulation of cellular processes connected 
with melanomagenesis, we studied anticancer activity of rosuvastatin against human melanoma 
cells in vitro. In our study melanoma cell lines (A549 and WM1552C) established from a primary 
superficial spreading melanoma were used. Cells were treated with rosuvastatin at concentrations 
ranged from 10-5000μg/ml for 24-72h. To asses in vitro cytotoxicity of rosuvastatin MTT assay and 
real time cell growth analysis (xCELLigence system) were performed. We also analyzed induction 
of apoptosis and influence of rosuvastatin on cancer cell cycle progression. Our analysis revealed 
that rosuvastatin reduce viability of A549 melanoma cells. Cytotoxic effect was observed after 
24h incubation at concentration of 1000μg/ml. Under the same conditions rosuvastatin induced 
cell cycle arrest in G1 phase and influenced A549 cells migration. In turn, rosuvastatin exhibited 
relatively lower activity against WM1552C cells. We also did not observe induction of apoptosis 
in any of melanoma cell lines analyzed. The results of our study indicates that sensitivity to rosu-
vastatin is highly dependent on the tumor cell line assessed. However, concentrations required for 
decreasing cancer cells viability in vitro exceeds 10 to 50-fold plasma concentrations reached in 
patients treated with rosuvastatin, what probably preclude its use in melanoma chemoprevention.   
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Skin carcinogenesis is reduced  in immune-deprived Ccr10-deficient mice 
S Müller, A Hippe, J Noffke, A Kislat, E Bünemann and B Homey Heinrich Heine University 
Hospital, Düsseldorf, Germany
Skin cancer is the most common form of cancer in Germany with an incidence of 120 to 130 cases 
per 100,000 inhabitants. Previously, we established that the CC chemokine CCL27 is exclusively 
expressed in human skin and observed its progressive loss during cutaneous carcinogenesis (actinic 
keratosis, basal cell carcinoma, squamous cell carcinoma). Furthermore, the activation of the EGFR/
Ras signaling pathway resulted in the marked downregulation of CCL27 in keratinocytes in vitro and 
in the epidermis in vivo. Our recent findings suggest that CCL27 plays a crucial role in skin homeo-
stasis and that its progressive loss enhances cutaneous carcinogenesis. To further investigate the 
role of CCR10 signaling during cutaneous carcinogenesis, we took advantage of a Ccr10-deficient 
mouse strain and analyzed the role of Ccl27/Ccr10 in a two-stage chemo-carcinogenesis model by 
DMBA/TPA administration. Twelve-week-old Ccr10-deficient female BALB/c mice and wildtype 
(WT) controls received a single application of 25 mg/ 200 ml of the initiating agent DMBA followed 
by multiple applications of 5 mg/ 200 ml of the promoting agent TPA for 40 weeks. Repetitive TPA 
applications induced skin inflammation and after 9 weeks of DMBA/TPA treatment papilloma devel-
oped. During the experiment we measured the number of the occurring tumors per mouse and in 
addition, the tumor size at the end of the experiment. Surprisingly, Ccr10-deficient mice developed 
significantly less and smaller tumors when compared to WT controls, which was accompanied by 
a significantly increased survival of Ccr10-deficient mice (***p<0.0009). Since the DMBA/TPA 
model of cutaneous carcinogenesis critically depends on local skin inflammation, findings of the 
present study suggest that the loss of Ccr10 signaling within the skin impairs cutaneous inflammation 
and subsequently resulting in a lower frequency of tumor development. Ongoing experiments in 
an inflammation-independent UV-induced mouse model of cutaneous carcinogenesis will further 
elucidate the role of CCL27-CCR10-interactions.    
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Skin response to a carcinogen involves the pregnane X receptor 
A Elentner,2 D Ortner,2 F Sparber,1 M Schmuth2 and S Dubrac2 1 Institute for Microbiology, 
ETH Zürich, Zürich, Switzerland and 2 Department of Dermatology and Venereology, 
Innsbruck Medical University, Innsbruck, Austria
The pregnane X receptor (PXR) is a transcription factor expressed in liver and intestine that is acti-
vated by xenobiotic chemicals including drugs and environmental toxicants. Topical application 
of the tumour initiator 7,12-dimethylbenz(a)anthracene (DMBA) enhances PXR, CY1A1, CYP1B1, 
and CYP3A11, but not AHR expression. Surprisingly, PXR is expressed in Langerhans cells (LC), 
and DMBA-induced PXR up-regulation is largely impaired in Langerin+ cells-depleted skin. While 
PXR and AHR deficiency protects against DNA damage in epidermal cells, only PXR deficiency 
increases LC migration after skin exposure to low-dose of DMBA, potentially explaining the delay 
in skin carcinogenesis in PXR-deficient mice. Control of LC migration by PXR occurs via CCR7 
and autocrine TGF-beta1 signaling. Human cells and PXR-humanized mice established the human 
relevance of these findings. This is the first report suggesting that PXR might be involved in cutaneous 
carcinogenesis and thus a potential target for anti-cancer therapy.    
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The mammalian target of rapamycin (mTOR) signaling pathway is active in pre-invasive 
neoplastic skin proliferations
PM Brunner,1 K Jahn,1 F Kalthoff,2 H Kittler,1 E Kriehuber,2 A Stuetz2 and G Stingl1 1 Dpt. 
of Dermatology, Medical University of Vienna, Vienna, Austria and 2 Novartis Institutes for 
Biomedical Research, Vienna, Austria
The mammalian target of rapamycin (mTOR) is a gatekeeper for various cellular signals which 
control cell growth, proliferation, and metabolism. mTOR is dysregulated in various human diseases 
such as cancers and cardiovascular disorders. There is evidence that PI3K-mTOR cell signaling is 
active in squamous cell carcinomas (SCC) of the skin. However, there is only limited data on the 
activation of components of this pathway in pre-invasive neoplastic proliferations as compared to 
healthy control skin (HC). In our study, we evaluated immunohistological stainings of skin biopsies 
with antibodies specific for phosphorylated forms of Akt as well as ribosomal S6 protein, a down-
stream substrate of mTOR. We found a significant increase of these pathway activation markers 
not only in SCC (n=8) and SCC in situ (Bowen’s disease, BD, n=9), but also in actinic keratoses 
(AK) (n=13) when compared to normal, healthy appearing skin (n=22). These results indicate that 
the up-regulation of this pathway is associated with even early stages of enhanced keratinocyte 
proliferation and may be operative during the progression of these pre-invasive conditions to an overt 
carcinoma. Remarkably, the staining data for phos-(S473) Akt support the notion that an increased 
PI3K-mTOR pathway activity may already be seen in sun-damaged skin lesions (n=22), although 
other markers such as phos-(S235/6)-S6 did not reveal a statistically significant difference to normal 
skin. From these data we conclude that targeting the mTOR signaling pathway might be a treatment 
option of pre-invasive neoplastic skin proliferations such as AK and BD.    
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The role of micro RNA 181a in cutaneous squamous cell carcinoma
J Neu,1 P Dziunycz,1 K Lefort,2 SN Freiberger,1 G Iotzova-Weis,1 G Dotto2 and G Hofbauer2 
1 University Hospital Zürich, Zürich, Switzerland and 2 Biochemistry, University of Lausanne, 
Epalinges, Switzerland
Pilot experiments show low abundance of miR-181a (among others) in squamous cell carcinoma 
(SCC). Due to the loss of its negative regulatory capacity caused by its lowered expression, functional 
properties such as cellular proliferation or migration might be elevated, explaining the cancerous 
behavior of these cells. Preliminary data confirm our hypothesis, because artificial upregulation 
of this particular micro RNA leads to significant reduction in cellular proliferation. Inversely, miR-
181a downregulation in patient derived healthy keratinocytes as well as in HaCaT cells (a cell line 
representing normal human keratinocytes) provokes increased proliferation, mimicking cancerous 
behavior at least in part. Real time PCR analysis of primary keratinocytes treated with a miR-181a 
inhibitor revealed increased RNA levels of the proto-oncogene KRas which may well explain the 
observed switch in cellular proliferation rates and might point out miR-181a’s important role in 
cutaneous SCC.    
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The TRAF-interacting protein (TRAIP) is a regulator of the spindle assembly checkpoint 
T Gleich,1 C Chapard,1 P Meraldi,2 D Bachmann,1 D Hohl1 and M Huber1 1 Service 
of Dermatology, CHUV, Lausanne, Switzerland and 2 Cell Physiology and Metabolism, 
University of Geneva, Geneva, Switzerland
The TRAF-interacting protein (TRAIP) is a ubiquitously expressed nucleolar E3 ubiquitin ligase that 
interacts with CYLD, SYK and DNA Polymerase h. Mutations in the CYLD gene cause the Brooke-
Spiegler syndrome characterized by the presence of skin appendage tumors such as cylindromas 
and trichoepitheliomas. Accurate chromosome segregation during mitosis is temporally and spatially 
coordinated by fidelity-monitoring checkpoint systems. Deficiencies in these checkpoint systems 
can lead to chromosome segregation errors and aneuploidy, potentially promoting tumorigenesis. 
TRAIP knock-down in keratinocytes leads to cell cycle arrest in the G1/S phase. We report here 
that TRAIP was preferentially localized around mitotic chromosomes in early mitosis and incor-
porated into nuclear-derived foci and prenucleolar bodies upon mitosis exit and early G1 phase. 
Its functional inactivation in HeLa cells by siRNAs accelerated the early mitosis progression from 
nuclear envelope breakdown to anaphase onset and increased the percentages of chromosome 
alignment defects in metaphase and lagging chromosomes in anaphase compared to control cells. 
TRAIP depletion weakened the spindle checkpoint response in the presence of nocodazole and 
significantly reduced kinetochore levels of MAD2 but not of other spindle checkpoint proteins. 
These results imply that TRAIP is involved in the spindle assembly checkpoint by regulating MAD2 
abundance at kinetochores and the accurate distribution of chromosomes between daughter cells. 
Therefore, TRAIP is implicated in the control of mitosis and tumor development.    
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The transcription factor Snail expressed in cutaneous squamous cell carcinoma induces epi-
thelial–mesenchymal transition and down-regulates COX-2
M Shimokawa,1 M Ozawa,2 Y Higashi1 and T Kanekura1 1 Department of Dermatology, 
Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan 
and 2 Department of Biochemistry and Molecular Biology, Graduate School of Medical and 
Dental Sciences, Kagoshima University, Kagoshima, Japan
Cutaneous spindle cell squamous cell carcinoma (SCC) is a highly malignant variant of SCC. The 
presence of spindle-shaped cells with a sarcomatous appearance, which are derived from squamous 
cells, suggests that these cells are produced as a result of epithelial–mesenchymal transition (EMT). 
EMT is a complex process in which epithelial cells lose their polarity and cell–cell contacts, while 
also acquiring increased motility and invasiveness. Snail regulates EMT by binding to proximal 
E-boxes in the promoter region of E-cadherin and repressing its transcription. When examining 
the expression of EMT markers and Snail in spindle cell SCCs, we found that cyclooxygenase-2 
(COX-2) expression was down-regulated. Since it has been shown that COX-2 is constitutively over-
expressed in a variety of malignancies, the down-regulation of COX-2 expression was unexpected. 
The presence of E-box-like sequences in the promoter region of COX-2 prompted us to perform 
a more detailed analysis. We introduced a Snail expression vector into keratinocyte-derived cell 
lines (HaKaT, HSC5, and A431 cells), and isolated stable transfectants. We determined that COX-2 
expression was down-regulated in cells expressing Snail. Consistent with these observations, reporter 
assays revealed that COX-2 promoter activity was repressed upon Snail overexpression. Thus Snail 
down-regulates COX-2 in these cells.    
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TLR4 is a negative regulator of keratinocyte proliferation 
G Iotzova-Weis, SN Freiberger, P Johansen, J Neu, Q Liu, P Dziunycz, L French and 
G Hofbauer Dermatology Clinic, Zürich, Switzerland
Our current study investigates the role of TLR4 in the proliferation capacity of normal keratinocytes. 
Our results using a blocking monoclonal antibody (HTA125) against TLR4 showed an unexpected, 
pronounced proliferation of keratinocytes, assessed by BrdU proliferation assay. In addition, we 
abrogated the interaction between TLR4 and its accessory protein MDII using a specific blocking 
peptide for MDII and in parallel using a specific blocking peptide against TLR4 (viper vs control 
peptide cp7). Keratinocytes reacted with an increased proliferation in response to MDII peptide 
but not in response to viper. In addition, we detected that the blocking HTA125 antibody induces 
the phosphorylation of SAPK/JNK and ERK1/2 in primary keratinocytes. We also observed that with 
the subsequent growing of normal primary keratinocytes up to full confluence and differentiation, 
the surface expression of TLR4 increased significantly. This correlates with the differential TLR4 
expression within the layers in normal skin and skin from patients with Squamous cell carcinoma. 
Furthermore, we found that the tumor SCC13 cell line, stably expressing TLR4 showed lower pro-
liferation capacity and higher motility. SCC13 TLR4 positive tumours showed a decrease in their 
growth when injected subcutaneously into nude mice. On the contrary, knockdown of TLR4 by sh 
specific RNA against TLR4 increased significantly the proliferation capacity of HaCat keratinocytes 
in vitro and the in vivo.    
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Ubiquitin-Specific Protease 2 promotes chemo/phototherapy resistance in cutaneous T-cell 
lymphoma
T Wei, E Biskup and R Gniadecki Bispebjerg Hospital, Copenhagen, Denmark
In this study, we aim to investigate the roles of Ubiquitin-Specific Protease 2 (USP2) in the patho-
genesis and treatment of cutaneous T-cell lymphoma (CTCL). CTCL is the most common extra-nodal 
lymphoma arising from skin-homing T-lymphocytes. Mycosis fungoides (MF) and Sézary syndrome 
(SS) are the most common CTCL. To date, we still lack effective tools for diagnosis and treatment of 
CTCL. USPs are de-ubiquitinating enzymes which remove ubiquitin from protein and allow them 
salvage from proteasome degradation. Due to their protease activity and involvement in several 
diseases, USPs become potential targets for pharmacological interference. USP2 plays an important 
role in the protection of prostate cancer from apoptosis. Until now, the role of USP2 in CTCL has 
not been very clear. First, we set out to investigate the mRNA expression of USP2 in MF plaque, 
MF tumor, normal skin as well as psoriasis lesion. Furthermore, USP2 expression was examined 
among three CTCL cell lines, MyLa2000, Hut78 and SeAx, combined with chemo/phototherapy. 
Secondly, we examined how USP2 knockdown influenced apoptosis with or without chemo agent 
and phototherapy. Next, the signaling pathways involved in the function of USP2 were explored. 
Interestingly, USP2 showed decreased expression in MF plaque and tumor compared to normal 
and psoriasis biopsies. USP2 showed the highest expression in MyLa2000 among three CTCL 
cell lines. Upon the treatment of nutlin 3a and psoralen + UVA (PUVA) treatment, USP2 mRNA 
expression was significantly increased in MyLa2000 cells, not Hut-78 and SeAx. Combined with 
pro-apoptotic agents (nutlin 3a) and PUVA, USP2 knockdown decreased cell viability up to 50% 
compared to scramble control, suggesting targeting USP2 can improve CTCL patients’ response to 
certain chemotherapy and phototherapy. USP2 knockdown resulted in decreased MDM2 expression 
and upregulation of p53 target gene, p21, indicating the anti-apoptotic property of USP2 is p53- 
depended. Taken together, USP2 promotes chemo/phototherapy resistance in CTCL. In the future, 
we may retrieve better therapeutic outcome in CTCL by manipulating USP2.    
